MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/200/0.1/20.09.24 | Market Closed - Börse Stuttgart 19:12:18 31/05/2024 BST | ||
| 0.039 EUR | +8.33% |
|
| 1 month | -43.48% | ||
| 3 months | -43.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.039 | +8.33% |
| 30/05/24 | 0.036 | -2.70% |
| 29/05/24 | 0.037 | +19.35% |
| 28/05/24 | 0.031 | +19.23% |
| 27/05/24 | 0.026 | -36.59% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 07:12 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME8N0C |
| ISIN | DE000ME8N0C4 |
| Date issued | 13/02/2024 |
| Strike | 200 $ |
| Maturity | 20/09/2024 (110 Days) |
| Parity | 10 : 1 |
| Emission price | 0.08 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.189 € |
|---|---|
| Lowest since issue | 0.019 € |
| Spread | 0.006 € |
| Spread % | 13.04% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Warrants
- Warrant
